Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 39 people enrolled
- Started
- 5 Mar 2024
- Ended
- 5 Aug 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Medically tailored meals
- Noom®
- Usual care
- Record updated
- 15 October 2025
- Why it stopped
- Funding ended, unable to reach recruitment goal.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 18 years of age or older
- ability to read, write, and speak English
- ability to provide informed consent
- greater than 10% GLP-1 Receptor Agonist induced weight loss
- less than 30-days since GLP-1 Receptor Agonist cessation
- willing to participate
Who cannot take part
- major psychiatric illness or substance misuse that could impair ability to participate
- presence of a medical condition or dietary restriction precluding eating study meals or weight loss (e.g., medical condition requiring liquid diet, pregnancy, eating disorder)
- participation in a study or program involving medically tailored meals or Noom® within the past 12-months
Where in United States
- UT Southwestern Medical CenterDallas, United States
About the trial
What the trial wants to find out
Longitudinal studies show there is a steep increase in weight regain in the first 3-4 months after stopping GLP-1 receptor agonist medications (GLP-1s) and most patients regain most of their weight within a year. Insurers now question the utility of GLP-1s for weight loss as they are hesitant to cover these costs long-term (~$833 per person per month). Some patients would also prefer not to take these medications in perpetuity and are likely to struggle with lifelong adherence. These challenges present an opportunity to test alternative interventions, such as meal replacements and behavioral treatments, to support weight maintenance after successful weight loss with GLP-1s. This regimen would allow patients to benefit from significant weight loss in the first year of taking GLP-1s and use more cost effective and sustainable strategies for long-term maintenance.
The 3 groups in the trial
- Medically tailored mealsTreatment being tested
Participants will receive 10 medically tailored meals per week (40 meals per month) for four-months.
Treatment: Medically tailored meals and Usual care
- Noom®Treatment being tested
Participants will receive a paid Noom® subscription for four-months. Noom® is a subscription-based mobile application that provides food intake and exercise tracking and uses principles from psychology to motivate behavior change.
Treatment: Noom® and Usual care
- Usual carePlacebo, for comparison
Participants will receive usual care from their provider.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 October 2025